EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Griscelli Syndrome Type 2: Comprehensive Analysis of 149 New and Previously Described Patients with RAB27A Deficiency

Jesmeen Maimaris, Adriel Roa-Bautista, Mahreen Sohail, Claire Booth, Chiara Cugno, Lenka Chenchara, Tawfeg Ben Omran, Yael Hacohen, Ming Lim, Kimberly Gilmour, Gillian Griffiths, Kanchan Rao und 2 weitere

Journal of Clinical Immunology · 2025-12 · 45 (1)

DOI: 10.1007/s10875-024-01842-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology, online erschienen am 28.11.2024. Verfasst von Jesmeen Maimaris und 13 weiteren Autor:innen. Beteiligte Einrichtung: University College London UCL Institute of Immunity and Transplantation, London, UK. j.maimaris@ucl.ac.uk. Hauptthemen laut MEDLINE: rab27 GTP-Binding Proteins, Lymphohistiocytosis, Hemophagocytic, Piebaldism, Primary Immunodeficiency Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the National Institute for Health Research Integrated Academic Training scheme (JM)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Griscelli syndrome type 2 (GS2) is a rare, life-threatening immunodysregulatory disorder characterised by impaired cytotoxic activity leading to susceptibility to haemophagocytic lymphohistiocytosis (HLH) and hypopigmentation. We completed a literature review and analysis of clinical data of 149 patients with GS2 including 8 new patients. We identified three founder mutations which show diverse phenotypic profiles ( RAB27A c.244 C > T, p.R82C, c.514_518delCAAGC, p.Q172NfsX2, c.550 C > T, p.R184X). The most common presentation was HLH (119/149, 80%), with high proportion of central nervous system involvement (68/149, 46%). Features of partial albinism were present in 105 of 149 cases (70%). Hypopigmentation can be absent in GS2 and should not exclude the diagnosis. Patients with biallelic protein truncating variants (PTV) were more likely to have systemic HLH (44/56, 79%) and partial albinism (45/56, 80%), in comparison to hypomorphic variants (9/41, 22%; 20/41, 49%). Patients with hypomorphic variants presented later (5.4 years cf. 0.4 years, p = < 0.0001) and were more likely to have isolated CNS HLH (2% cf. 42%, p = 0.001). Mortality was high in the cohort (50/149, 34%). Survival of cases post-HLH who underwent transplantation is superior to un-transplanted patients, suggesting adequate HLH control followed by early HSCT is highly beneficial. Mortality was reduced in HSCT recipients versus the un-transplanted group where follow-up data was available (14% compared to 58%). Asymptomatic cases identified through family history/genetic screening may benefit from pre-emptive HSCT, but access and development of robust functional testing are required. High mortality related to HLH remains concerning and emphasises the need for improved molecular characterisation and clinical prognostic factors to guide management decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rab27 GTP-Binding ProteinsLymphohistiocytosis, HemophagocyticPiebaldismPrimary Immunodeficiency DiseasesMutationHumansMaleFemaleChild, PreschoolInfantChildPhenotypeHematopoietic Stem Cell TransplantationGenetic Association StudiesGenetic Predisposition to DiseaseAdolescentAlbinism

Substanzen

rab27 GTP-Binding ProteinsRAB27A protein, human

Autor:innen und Institutionen

  • University College London UCL Institute of Immunity and Transplantation, London, UK. j.maimaris@ucl.ac.uk.
  • Paediatric Immunology Department, Great Ormond Street Hospital for Children National Health Service (NHS) Foundation Trust, London, UK. j.maimaris@ucl.ac.uk.
  • Immunology department, Manchester University Hospital National Health Service (NHS) Foundation Trust, Manchester, UK.
  • Paediatric department, Barts Hospital National Health Service (NHS) Foundation Trust, London, UK.
  • Paediatric Immunology Department, Great Ormond Street Hospital for Children National Health Service (NHS) Foundation Trust, London, UK.
  • UCL Great Ormond Street Institute of Child Health, London, UK.

Förderung

  • This work was supported by the National Institute for Health Research Integrated Academic Training scheme (JM).

Zitieren

APA

Maimaris, J., Roa-Bautista, A., Sohail, M., Booth, C., Cugno, C., Chenchara, L., Omran, T. B., Hacohen, Y., Lim, M., Gilmour, K., Griffiths, G., Rao, K., Elfeky, R., & Kusters, M. (2025). Griscelli Syndrome Type 2: Comprehensive Analysis of 149 New and Previously Described Patients with RAB27A Deficiency. Journal of Clinical Immunology, 45(1). https://doi.org/10.1007/s10875-024-01842-2

Vancouver

Maimaris J, Roa-Bautista A, Sohail M, Booth C, Cugno C, Chenchara L, et al. Griscelli Syndrome Type 2: Comprehensive Analysis of 149 New and Previously Described Patients with RAB27A Deficiency. Journal of Clinical Immunology. 2025;45(1). doi:10.1007/s10875-024-01842-2

BibTeX
@article{Maimaris2025,
  author = {Maimaris, Jesmeen and Roa-Bautista, Adriel and Sohail, Mahreen and Booth, Claire and Cugno, Chiara and Chenchara, Lenka and Omran, Tawfeg Ben and Hacohen, Yael and Lim, Ming and Gilmour, Kimberly and Griffiths, Gillian and Rao, Kanchan and Elfeky, Reem and Kusters, Maaike},
  title = {Griscelli Syndrome Type 2: Comprehensive Analysis of 149 New and Previously Described Patients with RAB27A Deficiency},
  journal = {Journal of Clinical Immunology},
  year = {2025},
  volume = {45},
  number = {1},
  doi = {10.1007/s10875-024-01842-2}
}
Kostenlos starten →